Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction
Open Access
- 24 June 2009
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- No. 34,p. 5091-5093
Abstract
Oligobenzamide inhibitors of the p53–hDM2 protein–protein interaction are described.Keywords
This publication has 37 references indexed in Scilit:
- Design, Synthesis, and Evaluation of an α-Helix Mimetic Library Targeting Protein−Protein InteractionsJournal of the American Chemical Society, 2009
- Total Synthesis of Vinblastine, Vincristine, Related Natural Products, and Key Structural AnaloguesJournal of the American Chemical Society, 2009
- β-Peptides with improved affinity for hDM2 and hDMXBioorganic & Medicinal Chemistry, 2009
- Synthesis and Biological Evaluation of a 5-6-5 Imidazole-Phenyl-Thiazole Based α-Helix MimeticOrganic Letters, 2008
- Synthesis of functionalised aromatic oligamide rodsOrganic & Biomolecular Chemistry, 2007
- Heterocyclic α-helix mimetics for targeting protein–protein interactionsBioorganic & Medicinal Chemistry Letters, 2007
- Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-xLJournal of the American Chemical Society, 2005
- Terphenyl‐Based Helical Mimetics That Disrupt the p53/HDM2 InteractionAngewandte Chemie International Edition, 2005
- Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in CellsJournal of Medicinal Chemistry, 2005
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 2004